KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other financing activities (2017 - 2025)

Historic Other financing activities for Aquestive Therapeutics (AQST) over the last 7 years, with Q3 2025 value amounting to $7000.0.

  • Aquestive Therapeutics' Other financing activities fell 1250.0% to $7000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3000.0, marking a year-over-year increase of 10003.8%. This contributed to the annual value of $4.6 million for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Other financing activities is $7000.0, which was down 1250.0% from $8000.0 recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Other financing activities ranged from a high of $9.1 million in Q1 2023 and a low of -$7.9 million during Q4 2023
  • Over the past 3 years, Aquestive Therapeutics' median Other financing activities value was $6000.0 (recorded in 2025), while the average stood at $424000.0.
  • The largest annual percentage gain for Aquestive Therapeutics' Other financing activities in the last 5 years was 9977.23% (2024), contrasted with its biggest fall of 9994.5% (2024).
  • Over the past 3 years, Aquestive Therapeutics' Other financing activities (Quarter) stood at -$7.9 million in 2023, then skyrocketed by 99.77% to -$18000.0 in 2024, then soared by 138.89% to $7000.0 in 2025.
  • Its last three reported values are $7000.0 in Q3 2025, $8000.0 for Q2 2025, and $6000.0 during Q1 2025.